ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

Should scPharmaceuticals, Inc.’s resubmission of Furoscix (furosemide injection) for US Food and Drug Administration approval prove successful, it will also have data to make its case to payers in the form of topline results from the FREEDOM-HF study, showing that the product was able to reduce costs related to heart failure by nearly $18,000 per patient.

The Burlington, MA-based company announced results on 13 July from FREEDOM-HF, a Phase III trial designed to provide a real-world evaluation of Furoscix’s ability to decrease hospital admissions and economic impact among heart failure patients, comparing the drug-device combination against historical controls treated with intravenous furosemide